Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $40.67.

Several analysts have issued reports on SLN shares. The Goldman Sachs Group lowered their target price on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday, March 4th. BMO Capital Markets decreased their price objective on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. Finally, Morgan Stanley lowered their price target on shares of Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th.

Silence Therapeutics Stock Down 6.8 %

Shares of SLN stock opened at $3.44 on Monday. Silence Therapeutics has a 12-month low of $3.19 and a 12-month high of $24.38. The company has a 50 day moving average of $4.64 and a 200-day moving average of $9.92. The firm has a market cap of $102.96 million, a P/E ratio of -2.19 and a beta of 1.08.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SLN. JPMorgan Chase & Co. purchased a new position in Silence Therapeutics during the fourth quarter valued at approximately $26,000. GAMMA Investing LLC boosted its holdings in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares during the period. Barclays PLC grew its position in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after purchasing an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Silence Therapeutics in the fourth quarter worth $69,000. Finally, Virtus ETF Advisers LLC raised its position in shares of Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after buying an additional 6,098 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.